Match!

Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

Published on Jul 1, 2013in Molecular Cancer Therapeutics4.856
· DOI :10.1158/1535-7163.MCT-12-1162
Lotfi Abou-Elkacem3
Estimated H-index: 3
(RWTH Aachen University),
Susanne Arns9
Estimated H-index: 9
(RWTH Aachen University)
+ 4 AuthorsWiltrud Lederle22
Estimated H-index: 22
(RWTH Aachen University)
Sources
Abstract
The combination of target-specific drugs like bevacizumab with chemotherapeutics has improved treatment efficacy in advanced colorectal cancer (CRC). However, the clinical prognosis of metastatic CRCs is still poor, and novel drugs are currently assessed with respect to their efficacies in patients with CRCs. In a phase III study, the multikinase inhibitor regorafenib (BAY 73-4506) has recently been shown to prolong survival of patients with CRCs after standard therapies failed. In the present study, the activity of regorafenib was investigated in comparison with the angiogenesis inhibitor DC101 in the highly aggressive, murine CT26 metastatic colon cancer model. While a treatment for 10 days with DC101 given at a dose of 34 mg/kg every third day significantly delayed tumor growth compared with vehicle-treated animals, regorafenib completely suppressed tumor growth at a daily oral dose of 30 mg/kg. Regorafenib also induced a stronger reduction in tumor vascularization, as longitudinally assessed in vivo by dynamic contrast-enhanced MRI (DCE-MRI) and confirmed by immunohistochemistry. In addition, regorafenib inhibited the angiogenic activity more strongly and induced a three times higher apoptosis rate than DC101. Even more important, regorafenib completely prevented the formation of liver metastases, whereas in DC101-treated animals, the metastatic rate was only reduced by 33% compared with the vehicle group. In addition, regorafenib significantly reduced the amount of infiltrating macrophages. These data show that the multikinase inhibitor regorafenib exerts strong antiangiogenic, antitumorigenic, and even antimetastatic effects on highly aggressive colon carcinomas indicative for its high potential in the treatment of advanced CRCs. Mol Cancer Ther; 12(7); 1322–31. ©2013 AACR .
Figures & Tables
  • References (61)
  • Citations (82)
📖 Papers frequently viewed together
529 Citations
201359.10The Lancet
20 Authors (Axel Grothey, ..., Dirk Laurent)
1,131 Citations
201359.10The Lancet
564 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References61
Newest
#1Eric Van Cutsem (Katholieke Universiteit Leuven)H-Index: 126
#2Josep TaberneroH-Index: 90
Last. Carmen J. Allegra (UF: University of Florida)H-Index: 26
view all 15 authors...
Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previousl...
729 CitationsSource
#1Suzanne George (Harvard University)H-Index: 48
#2Qian Wang (Harvard University)H-Index: 13
Last. George D. Demetri (Harvard University)H-Index: 104
view all 17 authors...
Purpose Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib. Regorafenib is a structurally unique inhibitor of multiple cancer-associated kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclinical and early-phase trials. Because KIT and PDGFRremain drivers of GIST after resistance to imatinib and sunitinib, we performed a multicenter sing...
149 CitationsSource
#1Teresa Troiani (Seconda Università degli Studi di Napoli)H-Index: 35
#2Erika Martinelli (Seconda Università degli Studi di Napoli)H-Index: 31
Last. Floriana Morgillo (Seconda Università degli Studi di Napoli)H-Index: 32
view all 6 authors...
Introduction: Treatment of colorectal cancer (CRC) has changed dramatically over the past decade, mainly due to the advent of molecularly targeted agents. In particular, an improved understanding of the role of the angiogenesis pathway in CRC has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic CRC (mCRC) and at present is the only antiangiogenesis agent...
18 CitationsSource
#1Dirk StrumbergH-Index: 37
#2Max E. ScheulenH-Index: 31
Last. Klaus MrossH-Index: 32
view all 11 authors...
Globally, colorectal cancer (CRC) is the fourth most common cancer in men and the third most common cancer in women (Parkin et al, 2005). Despite effective screening, 20–25% of patients with CRC present with advanced, unresectable disease and are treated primarily with palliative systemic therapy (Hamilton and Grem, 1998). 5-Fluorouracil (5-FU)-based chemotherapy has long been the mainstay of systemic therapy for advanced or metastatic CRC (Cercek and Saltz, 2010). For first-line treatment, curr...
152 CitationsSource
#1Ondřej Májek (DKFZ: German Cancer Research Center)H-Index: 9
#2Adam Gondos (DKFZ: German Cancer Research Center)H-Index: 32
Last. Hermann Brenner (DKFZ: German Cancer Research Center)H-Index: 125
view all 9 authors...
Colorectal cancer is the most common cancer in Germany and the second most common cause of cancer-related deaths in both men and women (Husmann et al, 2010; GEKID, 2011). This underlines the need for effective colorectal cancer control. Analysis of population-based survival of cancer patients provides an invaluable tool for measuring progress in these activities. Until recently, analyses of population survival in Germany were based predominantly on data from the Saarland registry covering only 1...
40 CitationsSource
6 Citations
#1Klaus MrossH-Index: 32
#2A. FrostH-Index: 14
Last. Olaf ChristensenH-Index: 12
view all 11 authors...
Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose–escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors. Patients and Methods: Patients aged 18 years or older with advanced solid tumors refractory to standard treatment were recruited. Regorafenib was administered o...
195 CitationsSource
#1Edward Chu (University of Pittsburgh)H-Index: 39
Over the past 8 to 10 years, significant advances have been made in the treatment of metastatic colorectal cancer (mCRC). In particular, the development of the targeted biologic agents bevacizumab, cetuximab, and panitumumab, and their integration with cytotoxic chemotherapy regimens has led to improvements in clinical efficacy. Despite these gains, the overall impact of current targeted agents in the treatment of mCRC has been relatively modest, and while 2-year survival has improved, no gains ...
87 CitationsSource
#1Jason R. Hasenstein (UW: University of Wisconsin-Madison)H-Index: 3
#2Kelsey Kasmerchak (UW: University of Wisconsin-Madison)H-Index: 2
Last. Kevin R. Kozak (UW: University of Wisconsin-Madison)H-Index: 25
view all 7 authors...
Angiosarcomas are malignant endothelial cell tumors with few effective systemic treatments. Despite a unique endothelial origin, molecular candidates for targeted therapeutic intervention have been elusive. In this study, we explored the tunica internal endothelial cell kinase 2 (Tie2) receptor as a potential therapeutic target in angiosarcoma. Human angiosarcomas from diverse sites were shown to be universally immunoreactive for Tie2. Tie2 and vascular endothelial growth factor receptor (VEGFR)...
27 CitationsSource
#1Axel GrotheyH-Index: 66
#2Alberto SobreroH-Index: 48
Last. Eric Van CutsemH-Index: 126
view all 10 authors...
LBA385 Background: Regorafenib (BAY 73-4506) is an oral multikinase inhibitor of a broad range of angiogenic, oncogenic, and stromal kinases. The phase III CORRECT trial was conducted to evaluate efficacy and safety of regorafenib in pts with mCRC who had progressed after all approved standard therapies. Methods: Enrollment criteria included documented mCRC and progression during or ≤3 months after last standard therapy. Pts were randomized 2:1 to receive regorafenib (160 mg od po, 3 weeks on/1 ...
67 CitationsSource
Cited By82
Newest
#1Won Mook Choi (UOU: University of Ulsan)H-Index: 33
#2Jonggi Choi (UOU: University of Ulsan)H-Index: 7
Last. Min-Hee Ryu (UOU: University of Ulsan)H-Index: 31
view all 13 authors...
Source
#1Anne DemolsH-Index: 15
#2Ivan Borbath (Cliniques Universitaires Saint-Luc)H-Index: 20
Last. Stéphane HolbrechtsH-Index: 6
view all 12 authors...
ABSTRACT Background There is a high unmet clinical need for treatments for advanced/metastatic biliary tract cancers (BTC) after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies. Patients and Methods REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase 2 study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic BTC that progre...
1 CitationsSource
#1Changhoon Yoo (UOU: University of Ulsan)H-Index: 17
#2Seonggyu Byeon (CBNU: Chungbuk National University)
Last. Il-Hwan Kim (Inje University)H-Index: 15
view all 16 authors...
BACKGROUND & AIMS: Regorafenib demonstrated a clinical benefit for patients with unresectable hepatocellular carcinoma (uHCC) in the phase III RESORCE trial. Considering the heterogeneity of uHCC and discrepancies in its characteristics between prospective trials and daily practice, real-life evidence is necessary. METHODS: This multicentre, retrospective analysis was performed by the Korean Cancer Study Group. In total, 440 patients who received regorafenib between January 2017 and November 201...
Source
#2Sung-Ying Huang (Mackay Memorial Hospital)H-Index: 6
Last. Sheng-Chun ChiuH-Index: 10
view all 5 authors...
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Regorafenib is a multi-kinase inhibitor and the second-line treatment for HCC. Since the PI3K/Akt/mTOR signaling pathway is dysregulated in HCC, we evaluated the therapeutic effects of regorafenib combined with a dual PI3K/mTOR inhibitor BEZ235 in the human HCC cell lines (n = 3). The combined treatment with BEZ235 and regorafenib enhanced the inhibition of cell proliferation and increased the expression of cleaved...
Source
AIM: Regorafenib is an oral multikinase inhibitor with clinical efficacy in a range of advanced solid tumors. A population pharmacokinetic (PK) model was developed to evaluate the variability of the PK of regorafenib and its pharmacologically active metabolites M-2 and M-5 in solid tumors. METHODS: The model was initially developed using densely sampled phase 1 data and information on food intake to incorporate enterohepatic circulation (EHC) that was identified to considerably contribute to the...
Source
#1Florian Bürtin (University of Rostock)H-Index: 3
#1Florian BürtinH-Index: 1
Last. Michael LinnebacherH-Index: 25
view all 3 authors...
Colorectal cancer (CRC) is the third most common diagnosed malignancy among both sexes in the United States as well as in the European Union. While the incidence and mortality rates in western, high developed countries are declining, reflecting the success of screening programs and improved treatment regimen, a rise of the overall global CRC burden can be observed due to lifestyle changes paralleling an increasing human development index. Despite a growing insight into the biology of CRC and man...
1 CitationsSource
#1Khurum Khan (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
#1Khurum KhanH-Index: 15
Last. Nazim Serdar TurhalH-Index: 1
view all 11 authors...
In colorectal cancer (CRC), imaging is important in determining tumor stage, selecting treatment strategies, and in assessing response to therapy. However, some challenges remain with established imaging techniques, such as computed tomography, and with some commonly used response criteria, such as Response Evaluation Criteria in Solid Tumors, which measures change in size of several target lesions instead of change in tumor morphology or metabolic function. In addition, these assessments are no...
1 CitationsSource
#1Soon Kyu LeeH-Index: 5
#2Jeong Won JangH-Index: 26
Last. Seung Kew YoonH-Index: 16
view all 7 authors...
Source
#1Satoshi Takagi (Azabu University)H-Index: 15
#2Hiroki Yamazaki (OPU: Osaka Prefecture University)H-Index: 1
Last. Kenji Hosoya (Hokkaido University)H-Index: 6
view all 6 authors...
In humans, contrast-enhanced CT (CECT) has been used to indirectly assess the antiangiogenic effects demonstrated by a number of tyrosine kinase inhibitors. This retrospective, cross-sectional study aimed to quantitatively evaluate changes in tumor contrast-enhancement (CE) using CECT in solid tumor-bearing dogs treated with toceranib phosphate (TOC). The changes in tumor size and CE were measured using the Hounsfield unit (HU) scale in CECT images before TOC treatment and between 30 and 90 days...
Source
#1Faysal Dane (Marmara University)H-Index: 15
#2Kirhan Ozgurdal (Bayer USA: Bayer Corporation)
Last. Hasan Şenol Coşkun (Akdeniz University)H-Index: 6
view all 13 authors...
Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC. Design Open-label, single-arm, phase IIIb study conducted between July 2013 and April 2015. Setting 11 tertiary centres in Turkey. Participants Eligible patients were adults with mCR...
Source